Yohei Takumi, Sachiko Arai, Chiaki Suzuki, Koji Fukuda, Akihiro Nishiyama, Shinji Takeuchi, Hiroki Sato, Kunio Matsumoto, Kenji Sugio, Seiji Yano. MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements. Cancer medicine. 2023. 12. 5. 5809-5820
Chiaki Suzuki, Akihiro Nishiyama, Sachiko Arai, Shoichiro Tange, Atsushi Tajima, Azusa Tanimoto, Koji Fukuda, Yohei Takumi, Hiroshi Kotani, Shinji Takeuchi, et al. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells. Cancer science. 2022. 113. 7. 2323-2335
Naohiro Yanagimura, Shinji Takeuchi, Koji Fukuda, Sachiko Arai, Azusa Tanimoto, Akihiro Nishiyama, Naohisa Ogo, Hiroyuki Takahashi, Akira Asai, Satoshi Watanabe, et al. STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. NPJ precision oncology. 2022. 6. 1. 11-11
Koushiro Ohtsubo, Kunio Miyake, Sachiko Arai, Koji Fukuda, Chiaki Suzuki, Hiroshi Kotani, Azusa Tanimoto, Akihiro Nishiyama, Shigeki Nanjo, Kaname Yamashita, et al. Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases. Cancer diagnosis & prognosis. 2022. 2. 3. 378-383
Koji Fukuda, Sakiko Otani, Shinji Takeuchi, Sachiko Arai, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Katsuhiko Naoki, Seiji Yano. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Cancer science. 2021. 112. 9. 3784-3795
Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.
(IASLC 2019 World Conference on Lung Cancer. 2019)
